Study on cell changes in lung cancer with RB1/TP53 gene changes
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at what happens when certain types of non-small cell lung cancer—those with changes in the RB1 and TP53 genes—start to change into another type of lung cancer after treatment. It may help find better ways to treat this specific kind of cancer in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have been diagnosed with stage III or IV non-small cell lung cancer that does not have neuroendocrine features.
- You have had testing that confirms both your RB1 and TP53 genes are inactivated.
- You have received at least one type of systemic treatment (like chemo, targeted therapy, or immunotherapy) and are being followed regularly.
- You agree to give blood and tissue samples for research before and during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to choose the best treatment for your lung cancer by creating a model of your tumor in the lab. It may help doctors find the most effective therapy for you.
This study looks at how EGFR-mutated lung cancer changes over time and tries to find markers that can predict how well you might respond to treatment. You will provide a tumor sample for genetic analysis.
This trial uses your tumor sample to guide personalized treatment decisions for certain lung cancers. It may help by matching you to a more targeted plan based on genetic testing and your prior treatment history.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
Hear when a new Neuroendocrine Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.